A cross border Life Sciences team advised UK-based Achilles Therapeutics plc (Nasdaq: ACHL) on its Initial Public Offering of 9,750,000 American Depositary Shares (ADSs) representing 9,750,000 ordinary shares at an initial public offering price of $18 per ADS. The total gross proceeds to Achilles from the offering were $175.5 million. Achilles has also granted the underwriters an option to purchase an additional 1,462,500 ADS at the initial public offering price.
Achilles is a clinical-stage, biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC), and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
For further details, please see the Achilles Therapeutics press release.